Plasma-activated medium (PAM) has emerged as a potential treatment option for synovial sarcoma, a rare form of cancer, according to a recent study conducted by a research team led by Osaka Metropolitan University. The team irradiated a mammalian cell culture medium with non-thermal atmospheric-pressure plasma to create PAM and conducted both in vitro and in vivo tests to assess its efficacy against synovial sarcoma. The findings of the study were published in the journal Biomedicines.
The research team, which included Graduate School of Medicine student Hana Yao, Associate Professor Hiromitsu Toyoda, Professor Hiroaki Nakamura, and Graduate School of Engineering Professor Jun-Seok Oh, demonstrated that PAM exhibited significant tumor-fighting effects against synovial sarcoma. Human synovial sarcoma cells treated with PAM showed a remarkable decrease in survival rate compared to the control group. Furthermore, in mice with synovial sarcoma, daily injections of PAM resulted in a substantial reduction in tumor volume and weight.
Professor Toyoda emphasized that the study not only highlighted the anticancer properties of PAM at both cellular and organismal levels but also noted the absence of significant side effects in the treated mice. The team is optimistic about further developing their research on PAM as a novel treatment approach for synovial sarcoma.
For more information on the study, readers can refer to the publication in Biomedicines titled “Anti-Tumor Effect of Non-Thermal Atmospheric Pressure Plasma-Activated Medium on Synovial Sarcoma: An In Vitro and In Vivo Study” by Hana Yao et al. The DOI for the article is 10.3390/biomedicines13030534.
This groundbreaking research conducted by Osaka Metropolitan University holds promise for the future of cancer treatment, particularly in the case of rare cancers like synovial sarcoma. The development of PAM as a therapeutic option could potentially revolutionize the way we approach and manage this challenging disease.
